Evidence map›Paper›PMID 34013378›Full record

ArticleOncology reports2021

Next‑generation sequencing analysis reveals that MTH‑3, a novel curcuminoid derivative, suppresses the invasion of MDA‑MB‑231 triple‑negative breast adenocarcinoma cells.

Yu-Jen Chiu, Fuu-Jen Tsai, Da-Tian Bau, Ling-Chu Chang, Min-Tsang Hsieh, Chi-Cheng Lu, Sheng-Chu Kuo, Jai-Sing Yang

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. BioMedicine · 2022
    Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yu-Jen ChiuDivision of Plastic and Reconstructive Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 11217, Taiwan, R.O.C.
Fuu-Jen TsaiHuman Genetic Center, China Medical University, Taichung 40402, Taiwan, R.O.C.
Da-Tian BauDepartment of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan, R.O.C.
Ling-Chu ChangChinese Medicinal Research and Development Center, China Medical University Hospital, Taichung 40402, Taiwan, R.O.C.
Min-Tsang HsiehChinese Medicinal Research and Development Center, China Medical University Hospital, Taichung 40402, Taiwan, R.O.C.
Chi-Cheng LuDepartment of Sport Performance, National Taiwan University of Sport, Taichung 40402, Taiwan, R.O.C.
Sheng-Chu KuoChinese Medicinal Research and Development Center, China Medical University Hospital, Taichung 40402, Taiwan, R.O.C.
Jai-Sing YangDepartment of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan, R.O.C.
China Medical University · TWNational Taiwan University of Sport · TWTaipei Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple‑negative breast cancer (TNBC) behaves aggressively in the invasive and metastatic states. Our research group recently developed a novel curcumin derivative, (1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2‑methoxy-4,1‑phenylene)bis(3-hydroxy2-hydroxymethyl)-2‑methyl propanoate (MTH‑3), and previous studies showed that MTH‑3 inhibits TNBC proliferation and induces apoptosis

Indexed as

Antineoplastic AgentsCell Line, TumorCell MovementCell ProliferationCell SurvivalDiarylheptanoidsDown-RegulationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansMAP Kinase Signaling SystemMatrix Metalloproteinase 9Sequence Analysis, RNATriple Negative Breast NeoplasmsAntineoplastic AgentsDiarylheptanoidsMatrix Metalloproteinase 9MMP9 protein, humananti‑metastasiscurcuminoid derivativeMTH‑3next generation sequencing analysistriple‑negative breast cancer (TNBC)

Identifiers

PMID34013378
PMCPMC8144931
OpenAlexW3161580820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.